Skip to content

Study · Systematic review · n = 6,359 · 2025

16 results

Tirzepatide for adults living with obesity.

Franco JV, Guo Y, Varela LB, Aqra Z, Alhalahla M, Medina Rodriguez M, Salvador Oscco EL, Patiño Araujo B, Banda S, Escobar Liquitay CM, Bracchiglione J, Meza N, Madrid E

The Cochrane database of systematic reviews30 Oct 2025Cited by 2 (Europe PMC)

PMID41161687 (opens in a new tab)DOI10.1002/14651858.cd016018 (opens in a new tab)PepBankPUB-41161687
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with obesity, the evidence is very uncertain about the effect of tirzepatide on serious adverse events versus placebo at 12 to 18 months.

    In plain wordsIn adults with obesity, it is very uncertain whether tirzepatide changes serious side effects compared with placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSerious adverse events (medium-term)
    Study

    n = 6,359

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    risk ratio
    0.99 RR
    serious adverse events, medium-term

    Source sentences

    Summary
    The evidence is very uncertain about the effect on serious adverse events (RR 0.99, 95% CI 0.88 to 1.12; 8 studies, 6359 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  2. 02HumanSystematic reviewSafety outcome

    In adults with obesity, tirzepatide may result in little to no difference in adverse events leading to withdrawal versus placebo at 12 to 18 months, although the reported risk ratio was 2.06.

    In plain wordsIn adults with obesity, the review reported a risk ratio of 2.06 for stopping tirzepatide due to side effects versus placebo (low-certainty evidence).

    Peptide
    Tirzepatide
    Outcome
    MixedAdverse events leading to withdrawal (medium-term)
    Study

    n = 6,359

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    risk ratio
    2.06 RR
    adverse events leading to withdrawal, medium-term

    Source sentences

    Summary
    Tirzepatide may result in little to no difference in adverse events leading to withdrawal (RR 2.06, 95% CI 1.21 to 3.52; 8 studies, 6359 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely results in a greater percentage reduction in body weight than placebo at 12 to 18 months.

    In plain wordsIn adults with obesity, tirzepatide likely led to a greater percentage weight loss than placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight change (medium-term)
    Study

    n = 6,317

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    mean difference
    −16.03%
    medium-term

    Source sentences

    Summary
    Tirzepatide versus placebo (medium-term: 12 to 18 months) Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference (MD) -16.03, 95% confidence interval (CI) -18.91 to -13.14; 8 studies, 6317 participants; moderate-certainty evidence)
    1 context sentence
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely results in little to no difference in major adverse cardiovascular events versus placebo at 12 to 18 months.

    In plain wordsIn adults with obesity, tirzepatide likely made little to no difference to major heart events compared with placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMajor adverse cardiovascular events (medium-term)
    Study

    n = 5,628

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    risk ratio
    0.75 RR
    MACE, medium-term

    Source sentences

    Summary
    Tirzepatide likely results in little to no difference in MACE (RR 0.75, 95% CI 0.34 to 1.66; I² = 0%; 7 studies, 5628 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely results in little to no difference in mortality versus placebo at 12 to 18 months.

    In plain wordsIn adults with obesity, tirzepatide likely made little to no difference to deaths compared with placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMortality (medium-term)
    Study

    n = 5,628

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    risk ratio
    0.79 RR
    mortality, medium-term

    Source sentences

    Summary
    Tirzepatide likely results in little to no difference in mortality (RR 0.79, 95% CI 0.34 to 1.83; 7 studies, 5628 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely results in little to no clinically important difference in quality of life on the IWQOL-Lite-CT physical function domain versus placebo at 12 to 18 months, although the mean difference was 9.91.

    In plain wordsIn adults with obesity, tirzepatide likely made little to no clinically important quality-of-life difference than placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    MixedQuality of life, IWQOL-Lite-CT physical function (medium-term)
    Study

    n = 5,020

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    mean difference
    9.91 points
    IWQOL-Lite-CT physical function, medium-term

    Source sentences

    Summary
    Tirzepatide likely results in little to no clinically important difference in quality of life as measured by the IWQOL-Lite-CT physical function domain (MD 9.91, 95% CI 7.81 to 12.02; 6 studies, 5020 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  7. 07HumanSystematic reviewSafety outcome

    In adults with obesity, tirzepatide may increase non-serious adverse events versus placebo at 12 to 18 months.

    In plain wordsIn adults with obesity, tirzepatide may cause more non-serious side effects than placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    IncreaseNon-serious adverse events (medium-term)
    Study

    n = 4,582

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    risk ratio
    1.33 RR
    non-serious adverse events, medium-term

    Source sentences

    Summary
    Tirzepatide may result in an increase in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 studies, 4582 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely increases the number of people achieving a 5% weight reduction versus placebo at 12 to 18 months.

    In plain wordsIn adults with obesity, tirzepatide likely made a 5% weight loss more common than placebo at 12 to 18 months.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAchieving 5% weight reduction (medium-term)
    Study

    n = 4,455

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg to 15 mg once weekly · injection · 12 to 18 monthsAs given in this study (human).

    Measurements

    risk ratio
    3.6 RR
    5% weight reduction, medium-term

    Source sentences

    Summary
    and an increase in the number of people achieving a 5% weight reduction (risk ratio (RR) 3.60, 95% CI 2.44 to 5.30; I2 = 86%; 5 studies, 4455 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (medium-term: 12 to 18 months)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  9. 09HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely results in a greater percentage reduction in body weight than placebo at 3.5 years.

    In plain wordsIn adults with obesity, tirzepatide likely led to a greater percentage weight loss than placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight change (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    mean difference
    −15.66%
    long-term

    Source sentences

    Summary
    Tirzepatide versus placebo (long-term: 3.5 years) Tirzepatide likely results in a greater percentage reduction in body weight from baseline (MD -15.66, 95% CI -19.14 to -12.18; 1 study, 1032 participants; moderate-certainty evidence)
    1 context sentence
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  10. 10HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely increases the number of people achieving a 5% weight reduction versus placebo at 3.5 years.

    In plain wordsIn adults with obesity, tirzepatide likely made a 5% weight loss more common than placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAchieving 5% weight reduction (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    risk ratio
    2.81 RR
    5% weight reduction, long-term

    Source sentences

    Summary
    and an increase in the number of people achieving a 5% weight reduction (RR 2.81, 95% CI 2.33 to 3.38; 1 study, 1032 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  11. 11HumanSystematic reviewSafety outcome

    In adults with obesity, tirzepatide may result in an increase in non-serious adverse events versus placebo at 3.5 years, although the risk ratio was 1.05.

    In plain wordsIn adults with obesity, the review found low-certainty evidence on non-serious side effects with tirzepatide compared with placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    MixedNon-serious adverse events (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    risk ratio
    1.05 RR
    non-serious adverse events, long-term

    Source sentences

    Summary
    Tirzepatide may result in an increase in non-serious adverse events (RR 1.05, 95% CI 0.98 to 1.11; 1 study, 1032 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  12. 12HumanSystematic reviewSafety outcome

    In adults with obesity, the evidence is very uncertain about the effect of tirzepatide on serious adverse events versus placebo at 3.5 years.

    In plain wordsIn adults with obesity, it is very uncertain whether tirzepatide changes serious side effects compared with placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSerious adverse events (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    risk ratio
    1.14 RR
    serious adverse events, long-term

    Source sentences

    Summary
    The evidence is very uncertain about the effect on serious adverse events (RR 1.14, 95% CI 0.79 to 1.65; 1 study, 1032 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  13. 13HumanSystematic reviewSafety outcome

    In adults with obesity, tirzepatide may result in little to no difference in adverse events leading to withdrawal versus placebo at 3.5 years.

    In plain wordsIn adults with obesity, tirzepatide may make little to no difference to withdrawals due to side effects compared with placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAdverse events leading to withdrawal (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    risk ratio
    1.64 RR
    adverse events leading to withdrawal, long-term

    Source sentences

    Summary
    Tirzepatide may result in little to no difference in adverse events leading to withdrawal (RR 1.64, 95% CI 0.97 to 2.76; 1 study, 1032 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  14. 14HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide likely results in little to no difference in major adverse cardiovascular events versus placebo at 3.5 years.

    In plain wordsIn adults with obesity, tirzepatide likely made little to no difference to major heart and blood vessel events compared with placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMajor adverse cardiovascular events (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    risk ratio
    0.56 RR
    MACE, long-term

    Source sentences

    Summary
    Tirzepatide likely results in little to no difference in MACE (RR 0.56, 95% CI 0.22 to 1.42; 1 study, 1032 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  15. 15HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide may result in little to no clinically important difference in quality of life on the SF-36 physical component score versus placebo at 3.5 years.

    In plain wordsIn adults with obesity, tirzepatide may make little to no clinically important difference to quality of life compared with placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    No significant changeQuality of life, SF-36 physical component score (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    mean difference
    2.7 points
    SF-36 physical component score, long-term

    Source sentences

    Summary
    Tirzepatide may result in little to no clinically important difference in quality of life as measured by SF-36 physical component score (MD 2.70, 95% CI 0.00 to 5.40; 1 study, 1032 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.
  16. 16HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide may result in little to no difference in mortality versus placebo at 3.5 years.

    In plain wordsIn adults with obesity, tirzepatide may make little to no difference to deaths compared with placebo at 3.5 years.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMortality (long-term)
    Study

    n = 1,032

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    5 mg to 15 mg once weekly · injection · 3.5 yearsAs given in this study (human).

    Measurements

    risk ratio
    0.83 RR
    mortality, long-term

    Source sentences

    Summary
    Tirzepatide may result in little to no difference in mortality (RR 0.83, 95% CI 0.22 to 3.17; 1 study, 1032 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    Tirzepatide versus placebo (long-term: 3.5 years)
    Summary · context
    We included nine RCTs with 7111 participants, aged 36.1 to 65.25 years, primarily from middle- and high-income countries.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.